MAIA Biotechnology Inc./$MAIA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
- Ticker
- $MAIA
- Sector
- Health
- Primary listing
- AMEX
- Employees
- 13
- Headquarters
- Chicago, United States
- Website
- maiabiotech.com
MAIA Metrics
BasicAdvanced
$63M
-
-$0.49
-
-
Price and volume
Market cap
$63M
52-week high
$3.19
52-week low
$0.87
Average daily volume
322K
Financial strength
Current ratio
3.413
Quick ratio
3.296
Profitability
Management effectiveness
Return on assets (TTM)
-101.86%
Return on equity (TTM)
-341.51%
Valuation
Price to book
4.34
Price to tangible book (TTM)
4.34
Price to free cash flow (TTM)
-2.072
Free cash flow yield (TTM)
-48.26%
Free cash flow per share (TTM)
-0.497
Growth
Earnings per share change (TTM)
-35.90%
3-year earnings per share growth (CAGR)
-30.22%
What the Analysts think about MAIA
Analyst ratings (Buy, Hold, Sell) for MAIA Biotechnology Inc. stock.
Analyst projections of the future price of MAIA Biotechnology Inc. stock.
MAIA Financial Performance
Revenues and expenses
MAIA Earnings Performance
Company profitability
Upcoming events
No upcoming events
MAIA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.